| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document Help

Title:Vpliv zaviralcev imunskih nadzornih točk in kemoterapije na preživetje in kakovost življenja pacientov z napredovalim nedrobnoceličnim pljučnim rakom
Authors:ID Koser, Nataša (Author)
ID Vrbnjak, Dominika (Mentor) More about this mentor... New window
ID Fokter Dovnik, Nina (Comentor)
Files:.pdf MAG_Koser_Natasa_2025.pdf (1,21 MB)
MD5: DF11EAC9E2A5876F2A6D0D5C48F90237
 
Language:Slovenian
Work type:Master's thesis/paper
Typology:2.09 - Master's Thesis
Organization:FZV - Faculty of Health Sciences
Abstract:Uvod: Nedrobnocelični rak pljuč (NDRP) predstavlja približno 85 % pljučnih rakov, prognoza napredovale bolezni pa ostaja slaba. Namen zaključnega dela je bil raziskati, kako zdravljenje z zaviralci imunskih nadzornih točk (ZINT) v primerjavi z zdravljenjem s kemoterapijo v prvi liniji zdravljenja vpliva na preživetje pacientov z napredovalim NDRP in njihovo kakovost življenja. Metode: Uporabili smo deskriptivno metodo dela ter izvedli sistematični pregled strokovne in znanstvene literature v podatkovnih bazah CINAHL Ultimate (EBSCOhost), Cochrane Library in PubMed ter dodatno v referencah v pregledanih člankih. Kritično oceno raziskav smo izvedli z orodjem CASP, splošno oceno kakovosti pa MERGE, sintezo pa z opisno metodo. Rezultati: V končno analizi smo vključili 14 raziskav, 9 sistematičnih pregledov z metaanalizo in 5 randomiziranih kliničnih raziskav faze III. Rezultati kažejo, da zdravljenje z ZINT v prvi liniji zdravljenja pomembno podaljša celokupno preživetje in preživetje brez napredovanja bolezni v primerjavi s kemoterapijo. Večina raziskav poroča tudi o boljši ali vsaj ohranjeni kakovosti življenja pri pacientih, zdravljenih z ZINT. Razprava in zaključek: ZINT v primerjavi s kemoterapijo pomembno izboljšajo preživetje in kakovost življenja pacientov z napredovalim NDRP. Potrebne so nadaljnje raziskave dolgoročnih učinkov in obvladovanja imunsko pogojenih neželenih učinkov.
Keywords:zaviralci imunskih nadzornih točk, kemoterapija, napredovali nedrobnocelični rak pljuč, kakovost življenja, preživetje
Place of publishing:Maribor
Publisher:[N. Koser]
Year of publishing:2025
PID:20.500.12556/DKUM-96035 New window
UDC:612.017:616.277:616.24-006-052(043.2)
COBISS.SI-ID:262579459 New window
Publication date in DKUM:12.01.2026
Views:164
Downloads:72
Metadata:XML DC-XML DC-RDF
Categories:FZV
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share



Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:25.11.2025

Secondary language

Language:English
Title:The impact of immune checkpoint inhibitors and chemotherapy on survival and quality of life in patients with advanced non-small cell lung cancer
Abstract:Introduction: Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, and the prognosis of advanced disease remains poor. The aim of this thesis was to investigate how treatment with immune checkpoint inhibitors (ICIs), compared to chemotherapy as first-line therapy, affects the survival and quality of life of patients with advanced NSCLC. Methods: We used a descriptive research method and conducted a systematic review of professional and scientific literature in the databases CINAHL Ultimate (EBSCOhost), Cochrane Library, and PubMed, as well as additional references found in the reviewed articles. The critical appraisal of the studies was carried out with the CASP tool, the overall quality assessment with MERGE, and the synthesis was descriptive. Results: The final analysis included 14 studies, comprising nine systematic reviews with meta-analyses and five phase III randomized controlled trials. First-line treatment with ICIs significantly prolonged overall survival and progression-free survival compared to chemotherapy. Most studies reported improved or at least maintained quality of life in patients treated with ICIs. Discussion and conclusion: Compared to chemotherapy, ICIs significantly improve survival and quality of life in patients with advanced NSCLC. Further research is needed to evaluate long-term effects and to optimize the management of immune-related adverse events.
Keywords:check point inhibitors, chemotherapy, advanced non-small cell lung cancer, quality of life, survival


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica